Aduhelm to be Discontinued

[somarco]

Biogen will discontinue its controversial Alzheimer's disease drug aducanumab (Aduhelm), the company announcedopens in a new tab or window Wednesday.

The drugmaker will stop developing and selling aducanumab, an anti-amyloid monoclonal antibody that received FDA accelerated approvalopens in a new tab or window in 2021. Biogen also will terminate the confirmatory ENVISION trial, which was a requirement of the drug's accelerated approval.

Controversial Alzheimer's Drug Abandoned

Biogen will stop developing and selling aducanumab

www.medpagetoday.com

 

[sman]

Is this the one the gubment used as their reasoning for increasing Part B so much a couple of years ago?

 

[somarco]

yup . . .

 

[StephanieCJ]

So, Part B is going to go down in cost now... Nevermind, I already know that answer.